Business
WuXi AppTec’s CRDMO Model: Linking Research, Development, and Manufacturing Across the Drug Development Lifecycle
SHANGHAI, SHANGHAI, CHINA, May 18, 2026 /EINPresswire.com/ -- In today’s life sciences industry, moving a drug candidate from discovery to patient access
About this update from Wuxi Apptec Co., Ltd. Class A
[{"type":"text","content":" SHANGHAI, SHANGHAI, CHINA, May 18, 2026 /EINPresswire.com/ -- In today’s life sciences industry, moving a drug candidate from discovery to patient access remains a long, complex, and resource-intensive process. Research, development, and manufacturing are often handled across separate stages, teams, and service providers, which can make coordination more difficult and slow overall progress. WuXi AppTec addresses these challenges through its CRDMO model, which brings research, development, and manufacturing together within one operating framework. The model supports customers ranging from biotech startups to global pharmaceutical companies and is designed to help reduce barriers that can delay the advancement of new medicines. CRDMO Model Covers Across the Drug Development Lifecycle WuXi AppTec’s CRDMO model combines research, development, and manufacturing within a single end-to-end framework. Instead of dividing these activities across separate service arrangements, the model supports the full lifecycle of a drug candidate, from early discovery through preclinical development, testing, and commercial manufacturing. Keeping these stages within one broader system can reduce the disruptions that often arise when projects move between multiple external providers. WuXi AppTec’s CRDMO model also supports closer alignment between scientific work and operational execution. Progress made in one phase can carry more directly into the next, helping teams move molecules toward milestones such as IND submission with greater continuity. This model is especially relevant for increasingly complex therapeutics, including small molecules, peptides, and oligonucleotides, where coordination across functions and stages can influence how effectively a program advances. How WuXi AppTec’s CRDMO Model Reshapes the Traditional CRO, CDMO, and CMO Approach Traditional CRO, CDMO, and CMO models usually focus on different segments of the drug development process. While each plays a role, dividing work across separate providers can create breaks between stages. Those breaks may lead to delays, higher costs, and challenges related to knowledge transfer or process consistency. WuXi AppTec’s CRDMO model is structured to reduce that stop-and-start pattern. By bringing research, development, and manufacturing into one coordinated setup, the CRDMO model allows pr...